AR092496A1 - Tiofenilamidas no anuladas - Google Patents
Tiofenilamidas no anuladasInfo
- Publication number
- AR092496A1 AR092496A1 ARP130103210A ARP130103210A AR092496A1 AR 092496 A1 AR092496 A1 AR 092496A1 AR P130103210 A ARP130103210 A AR P130103210A AR P130103210 A ARP130103210 A AR P130103210A AR 092496 A1 AR092496 A1 AR 092496A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cycloalkyl
- heteroaryl
- alkyl
- heterocycloalkyl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 abstract 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 14
- 125000003107 substituted aryl group Chemical group 0.000 abstract 13
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 3
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000004461 halocycloalkylalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Compuestos útiles para tratar aterosclerosis, neoplasias, enfermedad renal y hepática. Reivindicación 1: Compuestos de la fórmula (1), en la que: R¹ y R² se eligen con independencia entre H, alquilo, haloalquilo, alcoxialquilo, haloalcoxialquilo, cicloalquilo, cicloalquilalquilo, halocicloalquilo, halocicloalquilalquilo, arilo sustituido, arilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido, heteroarilalquilo sustituido, aminocarbonilo sustituido, alcoxicarbonilo, haloalcoxicarbonilo y carboxi, dichos arilo sustituido, arilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido y heteroarilalquilo sustituido están sustituidos por R¹⁴, R¹⁵ y R¹⁶, y dicho aminocarbonilo sustituido está sustituido sobre el átomo de nitrógeno por uno o dos sustituyentes elegidos con independencia entre H, alquilo, cicloalquilo, haloalquilo, alquilcicloalquilo cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo y alcoxialquilo; R³ es un arilo sustituido, arilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido o heteroarilalquilo sustituido, dichos arilo sustituido, arilalquilo sustituido, heterocicloalquilo sustituido, heterocicloalquilalquilo sustituido, heteroarilo sustituido y heteroarilalquilo sustituido están sustituidos por R¹⁷, R¹⁸ y R¹⁹; R⁴ es H o alquilo; R⁵ y R⁶ se eligen con independencia entre H, alquilo y cicloalquilo; R⁷ es H, alquilo o cicloalquilo; A es NR⁸ o CR⁹R¹⁰; E es NR¹¹ o CR¹²R¹³; R⁸ y R¹¹ se eligen con independencia entre H, alquilo, haloalquilo, cicloalquilo, halocicloalquilo, cicloalquilalquilo o halocicloalquilalquilo; R⁹, R¹⁰, R¹² y R¹³ se eligen con independencia entre H, halógeno, alquilo, haloalquilo y cicloalquilo; o R⁵ y R¹² junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁰ y pueden estar sustituidos además por R²¹ y/o R²², pero en el caso de que R⁵ y R¹² junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R⁶ y R¹³ están ausentes; o R⁸ y R¹² junto con los átomos de nitrógeno y de carbono a los que están unidos forman un heterocicloalquilo sustituido o heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁰ y pueden estar sustituidos además por R²¹ y/o R²², pero en el caso de que R⁸ y R¹² junto con los átomos de carbono a los que están unidos formen un heteroarilo sustituido, entonces R¹³ está ausente; o R⁹ y R¹¹ junto con los átomos de nitrógeno y de carbono a los que están unidos forman un heterocicloalquilo sustituido o heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁰ y pueden estar sustituidos además por R²¹ y/o R²², pero en el caso de que R⁹ y R¹¹ junto con los átomos de carbono a los que están unidos formen un heteroarilo sustituido, entonces R¹⁰ está ausente; o R⁹ y R¹² junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁰ y pueden estar sustituidos además por R²¹ y/o R²², pero en el caso de que R⁹ y R¹² junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R¹⁰ y R¹³ están ausentes; o R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, cicloalquenilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²³ y pueden estar sustituidos además por R²⁴ y/o R²⁵, pero en el caso de que R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R⁹ y R¹² están ausentes; o R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos forman un doble enlace; R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²³, R²⁴ y R²⁵ se eligen con independencia entre H, hidroxi, oxo, halógeno, alquilo, haloalquilo, cicloalquilo, halocicloalquilo, alcoxi, haloalcoxi, alcoxialquilo, haloalcoxialquilo, alcoxicarbonilo, carboxi y amino sustituido sobre el átomo de nitrógeno por uno o dos sustituyentes elegidos con independencia entre H, alquilo, cicloalquilo, haloalquilo, alquilcicloalquilo, cicloalquilalquilo, alquilcicloalquilalquilo, hidroxialquilo y alcoxialquilo; n es el número cero o 1; o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184125 | 2012-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092496A1 true AR092496A1 (es) | 2015-04-22 |
Family
ID=46967985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103210A AR092496A1 (es) | 2012-09-12 | 2013-09-10 | Tiofenilamidas no anuladas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9353102B2 (es) |
| EP (1) | EP2895481B1 (es) |
| JP (1) | JP6383357B2 (es) |
| KR (1) | KR20150054821A (es) |
| CN (1) | CN104619705B (es) |
| AR (1) | AR092496A1 (es) |
| BR (1) | BR112015004008A8 (es) |
| CA (1) | CA2878804A1 (es) |
| MX (1) | MX2015002624A (es) |
| RU (1) | RU2647587C2 (es) |
| TW (1) | TW201416364A (es) |
| WO (1) | WO2014040938A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101834857B1 (ko) * | 2015-01-05 | 2018-03-07 | 서울대학교산학협력단 | 제2형 당뇨병의 조기 진단을 위한 단백질 바이오 마커 |
| CA3017496A1 (en) * | 2016-03-11 | 2017-09-14 | The Research Foundation For The State University Of New York | A-truxillic acid derivatives and pharmaceutical compositions thereof |
| CN111690727A (zh) * | 2019-03-12 | 2020-09-22 | 南方医科大学南方医院 | Fabp5作为新型生物标志物用于诊断动脉粥样硬化 |
| BR112022026550A2 (pt) | 2020-06-27 | 2023-01-17 | Crescenta Biosciences | Composição de compostos que modulam o metabolismo celular e métodos de uso |
| US12138243B2 (en) | 2021-12-31 | 2024-11-12 | Crescenta Biosciences | Antiviral use of FABP4 modulating compounds |
| WO2024254161A2 (en) * | 2023-06-05 | 2024-12-12 | Celloram Inc. | Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making |
| WO2025226670A1 (en) * | 2024-04-23 | 2025-10-30 | Celloram, Inc. | Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1676834A1 (en) * | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| EP1937663A1 (en) * | 2005-09-29 | 2008-07-02 | Inpharmatica Limited | Thiophene derivatives as ppar agonists i |
| WO2008109856A2 (en) * | 2007-03-07 | 2008-09-12 | Xenon Pharmaceuticals Inc. | Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |
| US20100168084A1 (en) * | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
-
2013
- 2013-09-09 CA CA2878804A patent/CA2878804A1/en not_active Abandoned
- 2013-09-09 EP EP13762429.2A patent/EP2895481B1/en active Active
- 2013-09-09 BR BR112015004008A patent/BR112015004008A8/pt not_active Application Discontinuation
- 2013-09-09 KR KR1020157006187A patent/KR20150054821A/ko not_active Ceased
- 2013-09-09 JP JP2015530434A patent/JP6383357B2/ja not_active Expired - Fee Related
- 2013-09-09 CN CN201380047051.3A patent/CN104619705B/zh not_active Expired - Fee Related
- 2013-09-09 WO PCT/EP2013/068565 patent/WO2014040938A1/en not_active Ceased
- 2013-09-09 RU RU2015110644A patent/RU2647587C2/ru not_active IP Right Cessation
- 2013-09-09 MX MX2015002624A patent/MX2015002624A/es unknown
- 2013-09-10 AR ARP130103210A patent/AR092496A1/es unknown
- 2013-09-11 TW TW102132840A patent/TW201416364A/zh unknown
-
2015
- 2015-03-11 US US14/645,012 patent/US9353102B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2878804A1 (en) | 2014-03-20 |
| KR20150054821A (ko) | 2015-05-20 |
| EP2895481A1 (en) | 2015-07-22 |
| US20150183778A1 (en) | 2015-07-02 |
| TW201416364A (zh) | 2014-05-01 |
| US9353102B2 (en) | 2016-05-31 |
| CN104619705B (zh) | 2018-01-02 |
| WO2014040938A1 (en) | 2014-03-20 |
| RU2647587C2 (ru) | 2018-03-16 |
| JP6383357B2 (ja) | 2018-08-29 |
| BR112015004008A8 (pt) | 2018-01-23 |
| JP2015527384A (ja) | 2015-09-17 |
| HK1206771A1 (en) | 2016-01-15 |
| BR112015004008A2 (pt) | 2017-07-04 |
| RU2015110644A (ru) | 2016-11-10 |
| EP2895481B1 (en) | 2019-12-11 |
| MX2015002624A (es) | 2015-06-23 |
| CN104619705A (zh) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092496A1 (es) | Tiofenilamidas no anuladas | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis | |
| AR087984A1 (es) | Derivados biciclicos de dihidroquinolina-2-ona | |
| AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
| AR091464A1 (es) | Compuestos biciclicos de tiofenilamida | |
| AR092223A1 (es) | Derivados biciclicos de piridina | |
| AR126406A2 (es) | Compuestos de tetrazolinona y su uso | |
| AR096837A1 (es) | Heterociclos tricíclicos como inhibidores de proteínas bet | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR093518A1 (es) | Compuestos de pirrolpirimidina como inhibidores de quinasas | |
| ECSP11010912A (es) | Compuestos de pirrol | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
| AR098492A1 (es) | Derivados de purina | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR100879A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR084913A1 (es) | Derivados de aril-benzocicloalquil-amida | |
| AR061220A1 (es) | Derivados de tiazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |